Cargando…

Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG

PURPOSE: This study aimed to investigate the ability of Al(18)F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of (18)F-FDG PET/CT. METHODS: Prospective analysis of Al(18)F-NOTA-FAPI PET/CT and (18)F-FDG PET/CT scans of 31 patients from 05/202...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Zhehao, Han, Wei, Zhang, Qi, Zhao, Hongyue, Liu, Shan, Wang, Yan, He, Jin, Zhao, Changjiu, Tian, Lin, Fu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496317/
https://www.ncbi.nlm.nih.gov/pubmed/37700343
http://dx.doi.org/10.1186/s40644-023-00596-1
_version_ 1785105080171626496
author Lyu, Zhehao
Han, Wei
Zhang, Qi
Zhao, Hongyue
Liu, Shan
Wang, Yan
He, Jin
Zhao, Changjiu
Tian, Lin
Fu, Peng
author_facet Lyu, Zhehao
Han, Wei
Zhang, Qi
Zhao, Hongyue
Liu, Shan
Wang, Yan
He, Jin
Zhao, Changjiu
Tian, Lin
Fu, Peng
author_sort Lyu, Zhehao
collection PubMed
description PURPOSE: This study aimed to investigate the ability of Al(18)F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of (18)F-FDG PET/CT. METHODS: Prospective analysis of Al(18)F-NOTA-FAPI PET/CT and (18)F-FDG PET/CT scans of 31 patients from 05/2021 to 05/2022 were analyzed. Al(18)F-NOTA-FAPI imaging was performed in patients who had Ce-CT and FDG PET/CT and the diagnosis was still unclear. Follow-up histopathology or radiographic examination confirmed the findings. Radiotracer uptake, diagnostic performance, and TNM (tumor-node-metastasis) classifications were compared. RESULTS: A total of 31 patients with pancreatic carcinoma (all were adenocarcinoma) underwent Al(18)F-NOTA-FAPI-04 PET/CT, including 20 male and 11 female patients, with a mean age of 58.2 ± 8.5 years. FAPI-04 PET/CT imaging showed a higher value of SUV(max-15min/30min/60min), SUV(mean-15min/30min/60min), TBR(1), and TBR(2) in pancreatic carcinoma than FDG (all P < 0.01). The mean level of Al(18)F-NOTA FAPI-04 uptake values of the pancreatic ductal adenocarcinoma was higher than that of pancreatitis in both SUV(max-30min) (P < 0.01)(,) SUV(mean-30min) (P < 0.05), SUV(max-60min) (P < 0.01)(,) and SUV(mean-60min) (P < 0.01). The FAPI △SUV(max-1), △SUV(max-2), and △SUV(mean-2) uptake values of pancreatic carcinoma were higher than tumor-associated inflammation (all P < 0.01). TNM staging of 16/31 patients changed after Al(18)F-NOTA FAPI-04 PET/CT examination with all upstaging changes. CONCLUSION: Al(18)F-NOTA-FAPI-04 PET/CT at 15 and 30 min also demonstrated an equivalent detection ability of pancreatic lesion to (18)F-FDG PET/CT. Delayed-phase Al(18)F-NOTA-FAPI-04 PET/CT can help differentiate pancreatic carcinoma and tumor-associated inflammation. Al(18)F-NOTA FAPI-04 PET/CT also performed better than FDG PET/CT in TNM staging. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100051406. Registered 23 September 2021, https://www.chictr.org.cn/showproj.html?proj=133033
format Online
Article
Text
id pubmed-10496317
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104963172023-09-13 Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG Lyu, Zhehao Han, Wei Zhang, Qi Zhao, Hongyue Liu, Shan Wang, Yan He, Jin Zhao, Changjiu Tian, Lin Fu, Peng Cancer Imaging Research Article PURPOSE: This study aimed to investigate the ability of Al(18)F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of (18)F-FDG PET/CT. METHODS: Prospective analysis of Al(18)F-NOTA-FAPI PET/CT and (18)F-FDG PET/CT scans of 31 patients from 05/2021 to 05/2022 were analyzed. Al(18)F-NOTA-FAPI imaging was performed in patients who had Ce-CT and FDG PET/CT and the diagnosis was still unclear. Follow-up histopathology or radiographic examination confirmed the findings. Radiotracer uptake, diagnostic performance, and TNM (tumor-node-metastasis) classifications were compared. RESULTS: A total of 31 patients with pancreatic carcinoma (all were adenocarcinoma) underwent Al(18)F-NOTA-FAPI-04 PET/CT, including 20 male and 11 female patients, with a mean age of 58.2 ± 8.5 years. FAPI-04 PET/CT imaging showed a higher value of SUV(max-15min/30min/60min), SUV(mean-15min/30min/60min), TBR(1), and TBR(2) in pancreatic carcinoma than FDG (all P < 0.01). The mean level of Al(18)F-NOTA FAPI-04 uptake values of the pancreatic ductal adenocarcinoma was higher than that of pancreatitis in both SUV(max-30min) (P < 0.01)(,) SUV(mean-30min) (P < 0.05), SUV(max-60min) (P < 0.01)(,) and SUV(mean-60min) (P < 0.01). The FAPI △SUV(max-1), △SUV(max-2), and △SUV(mean-2) uptake values of pancreatic carcinoma were higher than tumor-associated inflammation (all P < 0.01). TNM staging of 16/31 patients changed after Al(18)F-NOTA FAPI-04 PET/CT examination with all upstaging changes. CONCLUSION: Al(18)F-NOTA-FAPI-04 PET/CT at 15 and 30 min also demonstrated an equivalent detection ability of pancreatic lesion to (18)F-FDG PET/CT. Delayed-phase Al(18)F-NOTA-FAPI-04 PET/CT can help differentiate pancreatic carcinoma and tumor-associated inflammation. Al(18)F-NOTA FAPI-04 PET/CT also performed better than FDG PET/CT in TNM staging. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100051406. Registered 23 September 2021, https://www.chictr.org.cn/showproj.html?proj=133033 BioMed Central 2023-09-12 /pmc/articles/PMC10496317/ /pubmed/37700343 http://dx.doi.org/10.1186/s40644-023-00596-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Lyu, Zhehao
Han, Wei
Zhang, Qi
Zhao, Hongyue
Liu, Shan
Wang, Yan
He, Jin
Zhao, Changjiu
Tian, Lin
Fu, Peng
Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
title Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
title_full Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
title_fullStr Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
title_full_unstemmed Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
title_short Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
title_sort clinical application of al(18)f-nota-fapi pet/ct in diagnosis and tnm staging of pancreatic adenocarcinoma, compared to (18)f-fdg
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496317/
https://www.ncbi.nlm.nih.gov/pubmed/37700343
http://dx.doi.org/10.1186/s40644-023-00596-1
work_keys_str_mv AT lyuzhehao clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT hanwei clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT zhangqi clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT zhaohongyue clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT liushan clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT wangyan clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT hejin clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT zhaochangjiu clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT tianlin clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg
AT fupeng clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg